FDA Determines Regulatory Review Period for TRAVATAN Patent Extension

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for the patent extension of TRAVATAN, a human drug product, following an application submitted to the Commissioner of Patents and Trademarks, Department of Commerce.